Symposia - 21/11/24

Doi : 10.14283/jpad.2018.39

Le texte complet de cet article est disponible en PDF.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Le texte complet de cet article est disponible en PDF.

Plan

S1-Apecs Trial of the Bace1 Inhibitor Verubecestat for Prodromal Alzheimer'S Disease. Jeffrey L. Cummings (Cleveland Clinic, Las Vegas, NV, USA)

S2-IS Bace1 a Suitable Drug Target for Prevention and Treatment of Alzheimer's Disease? Randall J. Bateman (Department of Neurology, St. Louis, MO, USA)

S4-Aβ Blood Based Test as Surrogate Markers of Cortical Amyloid Pathology for Clinical Trials on Alzheimer'S Disease. Pedro Pesini (Araclon Biotech-Grifols, Spain)

S5-Towards the Development of a Complete Solution for Patients with Alzheimer'S Disease (Ad). Rachelle Doody^1,2 ((1) Genentech, Inc., South San Francisco, CA, USA; (2) F. Hoffmann-La Roche Ltd, Basel, Switzerland)

S6-Endpoints for Early Alzheimer's Disease Clinical Trials: Interpretation and Application of the Draft Fda Guidance. Eric Siemers (Cogstate Ltd, New Haven, CT, USA)

S7-Disclosure of Alzheimer'S Risk Biomarkers to Cognitively Normal Older Adults. Athene Lee^1,2, Jessica Alber^1,2((1) Warren Alpert Medical School of Brown University, Providence, RI, USA; (2) Butler Hospital, Providence, RI, USA)

PRESENTATION AND PANEL DISCUSSION

Ambar (Alzheimer'S Management By Albumin Replacement) Phase Iib/Iii Results. Antonio Páez, (Grifols S.A., Barcelona, Spain)

ORAL COMMUNICATIONS

Oc1: Phase 2A Trial of Azd0530 Evaluating 18F-Fdg Pet, Safety, and Tolerability in Mild Alzheimer’S Dementia. Christopher H. van Dyck¹, Haakon B. Nygaard², Kewei Chen³, Michael C. Donohue⁴, Rema Raman⁴, Robert A. Rissman^4,5, James B. Brewer⁵, Robert A. Koeppe⁶, Tiffany W. Chow⁴, Michael S. Rafii⁴, R. Scott Turner⁷, Jeffrey A. Kaye⁸, Seth A. Gale⁹, Eric M. Reiman³, Paul S. Aisen⁴, Stephen M. Strittmatter1 ((1) Yale University School of Medicine, New Haven, USA; (2) The University of British Columbia, Vancouver, Canada; (3) Banner Alzheimer’s Institute, Phoenix, USA; (4) Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, USA; (5) University of California San Diego, La Jolla, USA; (6) University of Michigan, Ann Arbor, USA; (7) Georgetown University, Washington, DC, USA; (8) Oregon Health & Science University, Portland, USA; (9) Harvard Medical School, Boston, USA)

Oc2: Primary Results from a Phase Ii/Iii Trial of Intranasal Insulin: A Novel Multitarget Molecule And Delivery Mode for Ad Therapeutics. Suzanne Craft¹, Rema Raman², Tiffany Chow², Michael S Rafii², Robert A. Rissman³, James B. Brewer³, Michael Donohue², Chung-Kai Sun², Kelly Harless², Devon Gessert², Paul S. Aisen2 ((1) Wake Forest School of Medicine, Winston-Salem, USA; (2) University of Southern California, Los Angeles, USA; (3) University of California, San Diego , USA)

Oc3: Phase3 Clinical Trial for a Novel Oligosaccharide Targeting Multiple Aβ Fragments in Patients With Mild-Moderate Ad in China. Shifu Xiao¹, Zhenxin Zhang², Meiyu Geng³, GV-971 Study Group ((1) Department of Gerontology, Shanghai Mental Health Center, Shanghai Jiao Tong University, Shanghai, China; (2) Peking Union Medical College Hospital, Beijing, China; (3) State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China)

Oc4: Active Anti-Amyloid Immunotherapy With Ub-311 Vaccine: Design, Baseline Data And Study Update of a Phase Iia, Randomized, Doubleblind, Placebo-Controlled, 3-Arm Parallelgroup, Multicenter Study. Ajay Verma, Hui Jing Yu, Hui-Chen Chen, Chang Yi Wang on behalf of the UB-311 Phase IIa Study Team (United Neuroscience, Inc. Hauppauge, NY, USA)

Oc5: Elenbecestat In Mci-To-Moderate A L Z H E I M E R' S D I S E A S E : S A F E T Y A N D Effectiveness As Measured By Amyloid Pet And The Adcoms Clinical Endpoints. Shau Yu Lynch, June Kaplow, Jim Zhao, Shobha Dhadda, Johan Luthman, Bruce Albala (Eisai Inc., Woodcliff Lake, NJ, USA)

OC6: Allopregnanolone Regenerative Therapeutic for Mild Cognitive Impairment and Mild Alzheimer’S Disease: Phase 1B/2A Outcomes Update. Roberta D. Brinton1, Gerson D. Hernandez¹, Naoko Kono², Claudia M. Lopez¹, Christine Solinsky³, Kathleen Rodgers¹, Jin Gahm⁴, Dogu Aydogan⁴, Yonggang Shi⁴, Sonia Pawluczyk⁵, Meng Law⁶, Wendy Mack², Lon Schneider⁵((1) Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA; (2) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA; (3) School of Pharmacy, University of Southern California, Los Angeles, CA, USA; (4) USC Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, CA, USA; (5) Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; (6) Department of Radiology, University of Southern California, Los Angeles, CA, USA)

OC7: Impact of Amyloid Pet on the Management of Cognitively Impaired Patients: Results From The Ideas Study. Gil D. Rabinovici¹, Constantine Gatsonis², Charles Apgar³, Kiran Chaudhary¹, Ilana Gareen², Lucy Hanna², James Hendrix⁴, Bruce E. Hillner⁵, Cynthia Olson³, Orit Lesman-Segev¹, Justin Romanoff², Barry A. Siegel⁶, Rachel A. Whitmer⁷, Maria C. Carrillo4 on behalf of the IDEAS investigators ((1) Department of Neurology, University of California San Francisco, USA; (2) Center for Statistical Sciences, Brown University, USA; (3) American College of Radiology, USA; (4) Alzheimer's Association, USA; (5) Department of Medicine, Virginia Commonwealth University, USA; (6) Department of Radiology, Washington University, USA; (7) Division of Research, Kaiser Permanente, USA)

OC8: Safety and Efficacy of Estrogen Receptor-Β Targeted Phytoserm Formulation for Cognitive Complaints and Vasomotor Symptoms: Phase 1B/2A Trial Outcomes. Lon S. Schneider¹, Gerson Hernandez², Liqin Zhao³, Sonia Pawluczyk¹, Wendy J. Mack¹, Roberta D. Brinton² ((1) Keck School of Medicine of the University of Southern California, Los Angeles, USA; (2) University of Arizona, Center for Innovation in Brain Science, Tucson, USA; (3) University of Kansas – USA)

OC9: Interim Safety And Efficacy Results of Pilot Trial Of Gm-Csf/Sargramostim in Mild to Moderate Ad. Huntington Potter¹, Jonathan H. Woodcock, Timothy Boyd, Stefan H. Sillau, Thomas Borges, Brianne M. Bettcher, Joseph Daniels (Rocky Mountain Alzheimer's Disease Center, Department of Neurology University of Colorado School of Medicine, USA)

OC10: Untangled – Peptide-Based Inhibitors of Tau Aggregation as a Potential Treatment for Alzheimer'S Disease. David Allso^1,2, Anthony Aggidis¹, Nigel Fullwood¹, Mark Taylor^1,2, Penny Foulds^1,2, Shoona Vincent², Mark Dale² ((1) Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK; (2). Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK)

OC11: Safety and Efficacy of Lemborexant for Sleep-Wake Regulation in Patients With Irregular Sleep Wake Rhythm Disorder and Alzheimer'S Disease Dementia. Margaret Moline1, Mohammad Bsharat¹, Manuel Kemethofer², Gleb Filippov¹, Naoki Kubota³, Patricia Murphy¹ ((1) Eisai, Inc., Woodcliff Lake, USA; (2) The Siesta Group, Vienna, Austria (3) Eisai Co. Ltd., Tokyo, Japan)

OC12: Tau Pet Imaging as a Screening Tool for Clinical Trials of Disease Modifying Therapies. Adam S Fleisher², Michael J Pontecorvo², Michael D Devous², Ming Lu², Sergey Shcherbinin¹, Anupa K Arora², Mark A Mintun^1,2 ((1) Eli Lilly & Co, Indianapolis, IN, USA; (2) Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA)

OC13: Bace Inhibition by Verubecestat Produces a Rapid, Non-Progressive Reduction In Brain And Hippocampal Volume in Alzheimer’S Disease. Cyrille Sur¹, James Kost¹, David Scott², Katarzyna Adamczuk², Nick C Fox³, Jeffrey Cummings⁴, Pierre Tariot⁵, Paul Aisen⁶, Bruno Vellas⁷, Tiffini Voss¹, Yuki Mukai¹, David Michelson¹, Michael Egan1 ((1) Merck & Co., Inc., Kenilworth, NJ, USA; (2) Bioclinica, Newark, CA, USA; (3) University College London, London, UK; (4) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; (5) BannerAlzheimer’s Institute, Phoenix, AZ, USA; (6) University of California San Diego, San Diego, CA, USA; (7) Gerontopole, Toulouse University Hospital, Toulouse, France)

OC14: Distinct Tau Pet Patterns in Atrophydefined Subtypes of Alzheimer'S Disease. Rik Ossenkoppele^1,2, Gil D. Rabinovici³, Chul H. Lyoo⁴, Oskar Hansson^1,5((1) Lund University, Clinical Memory Research Unit, Lund, Sweden; (2) VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands; (3) Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center; (4) Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea; (5) Memory Clinic, Skåne University Hospital, Malmö, Sweden)

OC15: Cocoa Supplement And Multivitamin Outcomes Study of Cognitive Function (Cosmos-Mind): Design of a Large Randomized Clinical Trial. Laura D. Baker¹, Mark A. Espeland¹, Stephen R. Rapp¹, Sally A, Shumaker¹, Sarah A, Gaussoin¹, Howard D. Sesso², JoAnn E. Manson² ((1) Wake Forest School of Medicine, Winston-Salem, USA; (2) Brigham and Women's Hospital, Harvard Medical School, Boston, USA)

OC16: Rationale And Design of a Prospective, Randomized, Double-Blind, Dose-Comparison Safety and Tolerability Study Of Grf6019 in Mild-To-Moderate Alzheimer'S Disease. Jonas Hannestad, Ian Gallager, Katie Koborsi, S. Sakura Minami, Darby Stephens, Viktoria Kheifets, Steven Braithwaite (Alkahest, Inc., San Carlos -USA)

OC17: Machine Learning Algorithm Helps Identi F Y Non-Diagnosed Prodromal Alzheimer's Disease Patients in General Population. Olga Uspenskaya-Cadoz^1*, Chaitanya Alamuri^2*, Sam Khinda³, Yuliya Nigmatullina², Carolina Rubel³, Lanhui Wang², Mengting Yang², Tao Cao², Nikhil Kayal ((1) IQVIA CNS Center of Excellence; (2) IQVIA Analytics Center of Excellence; (3) IQVIA Project Leadership. *Both authors contributed to the abstract equally)

OC18: Abbv-8E12, a Humanized Anti-Tau Monoclonal Antibody, For Treating Early Alzheimer's Disease: Updated Design and Baseline Characteristics Of Phase 2 Study. Hana Florian¹, Steven E. Arnold², Randall J. Bateman³, Joel B. Braunstein⁴, Kumar Budur¹, Diana R. Kerwin⁵, Holly Soares¹, Deli Wang¹, David M. Holtzman³ ((1) AbbVie, Inc., North Chicago, IL, USA; (2) Massachusetts General Hospital, Boston, MA, USA; (3) Washington University, St. Louis, MO, USA; (4) C2N Diagnostics LLC, St. Louis, MO, USA; (5) Texas Health Presbyterian Hospital, Dallas, TX, USA)

OC19: Assessment of Clinical Meaningfulness Of Endpoints in the Generation Program By the Insights to Model Alzheimer'S Progression in Real Life (Imap) Study. A. Graf¹, V. Risson¹, S. Tzivelekis², A. Gustavsson³, V. Bezlyak¹, A. Caputo¹, P.N. Tariot⁴, J.B. Langbaum⁴, C. Lopez Lopez¹, V. Viglietta² ((1) Novartis Pharma AG; (2) Amgen, Inc.; (3) Quantify Research; (4) Banner Alzheimer's Institute)

OC20: Characterizing Clinical Severity Among Biomarker Positive Individuals: Applying the 2018 Nia-Aa Research Criteria for Alzheimer'S Disease to Four Large Study Cohorts. Roos J. Jutten¹, Rebecca E. Amariglio^2,3, Gad A. Marshall^2,3, Dorene M. Rentz^2,3, Wiesje M. Van der Flier¹, Philip Scheltens1, Keith A. Johnson^2,4, Reisa A. Sperling^2,3, Sietske A.M. Sikkes^1,3, Kathryn V. Papp^2,3 ((1) Alzheimer Center, VU University Medical Center, Amsterdam -The Netherlands; (2) Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA; (3) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA; (4) Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA)

OC21: Extension And Validation of an Amyloid Staging Model: Associations with Clinical Measures. Lyduine Collij¹, Fiona Heeman¹, Gemma Salvadó Blasco², Elles Konijnenberg³, Anouk den Braber⁴, Maqsood Yaqub¹, Pieter Jelle Visser³, Alle Meije Wink, Ir¹, Philip Scheltens³, Ronald Boellaard¹, Bart N.M. van Berckel¹, Juan Domingo Gispert López², Mark Schmidt⁵, Frederik Barkhof^1,6, Isadora Lopes Alves1 ((1) Dept. of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; (2) BarcelonaBeta Brain Research Center, Barcelona -Spain; (3) Alzheimer Center and Dept. of Neurology, VU University Medical Center, Amsterdam -The Netherlands; (4) Dept. of Biological Psychology, VU University Amsterdam -The Netherlands; (5) Janssen Pharmaceutica, Beerse -Belgium; (6) Institute of Neurology and Healthcare Engineering, University College London, London -United Kingdom)

OC22: Twenty-Four–Month Amyloid Pet Results of the Gantenerumab High-Dose Scarlet and Marguerite Road Open-Label Extension Studies. Gregory Klein¹, Paul Delmar², Carsten Hofmann¹, Danielle Abi-Saab², Mirjana Andjelkovic², Smiljana Ristic², Nicola Voyle³, Jacob Hesterman⁴, John Seibyl⁴, Ken Marek⁴, Ferenc Martenyi², Monika Baudler², Paulo Fontoura², Rachelle Doody² ((1) Roche Pharma Research and Early Development, Basel, Switzerland; (2) Roche/Genentech Product Development, Neuroscience, Basel, Switzerland; (3) Roche Products Ltd, Welwyn Garden City, UK; (4) InviCRO, LLC, Boston, MA, US)

OC23: Multi-Domain Interventions to Prevent Dementia: From Finger to World-Wide Fingers. Miia Kivipelto, On behalf of the World-Wide FINGERS network ((1) Karolinska Institutet, Department of Clinical Geriatrics, Center for Alzheimer Research, Stockholm, Sweden; (2) University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, Finland; (3) Imperial College London, NEA, School of Public Health, UK)

OC24: Identifying Risk of Cognitive Decline in Mild Cognitive Impairment for Population Enrichment of Clinical Trials. Christian Dansereau^1,2, Maor Zaltzhendler¹, Angela Tam^2,3, Pedro Rosa-Neto³, Serge Gauthier³, Pierre Bellec^2,4 ((1) Perceiv Research Inc., Montreal, Canada; (2) Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Canada; (3) Douglas Mental Health University Institute, McGill University, Canada; (4) Department of Computer Science and Operations Research, University of Montreal, Canada)

OC25: Study Update on Xanadu: Phase Ii Study of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer'S Disease. Craig Ritchie (Centre for Dementia Prevention, University of Edinburgh UK)

OC26: First Longitudinal Evaluation of the Tau Tracer [18F]Mk-6240 for the Use in Clinical Trials. Tharick A. Pascoal¹, Sulantha Mathotaarachchi¹, Mira Chamoun¹, Joseph Therriault¹, Robert Hopewell², Gassan Massarweh², Andrea L. Benedet¹, Min Su Kang¹, Jean-Paul Soucy², Serge Gauthier¹, Pedro Rosa-Neto¹ ((1) Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada; (2) Montreal Neurological Institute, McGill University, Montreal, Canada)

OC27: Implementation of the Nia-Aa Research Framework: Toward a Biological Definition of Alzheimer's Disease in Aibl. Samantha C Burnham^1,2, Preciosa M Coloma³, Qiao-Xing Li⁴, Steven Collins⁵, Greg Savage⁶, Simon Laws², James Doecke⁷, Paul Maruff⁸, Ralph N Martins^2,9, David Ames¹⁰, Christopher C Rowe¹¹, Colin L Masters⁴, Victor L Villemagne^4,11 ((1) eHealth, CSIRO, Parkville, VIC, Australia; (2) School of Medical Sciences, Edith Cowan University, Joondalup, Australia; (3) Product Development Personalised Health Care -Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland; (4) The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia; (5) Department of Pathology, University of Melbourne, Parkville, Australia; (6) Macquarie University, Sydney, Australia; (7) eHealth, CSIRO, Herston, QLD, Australia; (8) Cogstate Ltd., Melbourne, Australia; (9) Macquarie University, North Ryde, Australia; (10) National Ageing Research Institute, Melbourne, Australia ; (11) Austin Health, Melbourne, Australia)

OC28: The Neuroprotective Effect of a New Photobiomodulation Technique on Aβ25-35 Peptide-Induced Toxicity Dramatically Impact Gut Microbiota Dysbiosis. Jacques Touchon^1,2, Laura Auboyer³, Johann Meunier⁴, Laura Ceolin⁴, François J. Roman⁴, Rémy Burcelin⁵, Guillaume J. Blivet³ ((1) INSERM U1061, Montpellier, France; (2) Neurology Department, University of Montpellier, France; (3) REGEnLIFE SAS, Montpellier, France; (4) Amylgen SAS, Montferrier-sur-Lez, France; (5) Vaiomer SAS, Labège, France)

OC29: Elecsys® Csf Biomarker Immunoassays Demonstrate Concordance With Results of Amyloid-Pet Imaging In Aibl Patient Samples. Larry Ward¹, Samantha C. Burnham^4,7 Victor L. Villemagne^5,6, Qiao-Xin Li⁵, Steven Collins⁵, Christopher J Fowler⁵, Ekaterina Manuilova², Monika Widmann³, Stephanie Rainey-Smith⁷, Colin L Masters⁵, James D Doecke^1,8 ((1) Cooperative Research Council for Mental Health, Melbourne, Vic, Australia; (2) Roche Diagnostics GmbH, Penzberg, Germany; (3) Roche Diagnostics GmbH, Mannheim, Germany; (4) Commonwealth Scientific Industry and Research Organisation/Australian E-Health Research Centre, Parkville, Melbourne, QLD, Australia; (5) The Florey Institute, The University of Melbourne, Parkville, Australia; (6) Austin Health, Department of Molecular Imaging and Therapy, Center for PET, Heidelberg, Victoria, Australia; (7) School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia; 8. Commonwealth Scientific Industry and Research Organisation/ Australian E-Health Research Centre, Brisbane, QLD, Australia)

OC30: Cost-Effective, Multi-Step Enrichment Strategy for Clinical Trials Using Artificial Intelligence. Sulantha Mathotaarachchi, Tharick A. Pascoal, Mira Chamoun, Andrea L. Benedet, Min Su Kang, Joseph Therriault, Serge Gauthier, Pedro Rosa-Neto (McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada)

OC31: Trc-Pad: Accelerating Participant Recruitment in Ad Clinical Trials Through Innovation. Gustavo A. Jimenez-Maggiora¹, Rema Raman¹, Michael S. Rafii¹, Reisa Anne Sperling^2,3, Jeffrey Lee Cummings⁴, Paul S. Aisen¹ ((1) Alzheimer's Therapeutics Research Institute, University of Southern California, San Diego, CA, USA; (2) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; (3) Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; (4) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA)

OC32: Detecting Brain Amyloid Status Using Fully Automated Plasma Aβ Biomarker Assays. Sebastian Palmqvist¹, Shorena Janelidze¹, Erik Stomrud ¹, Henrik Zetterberg², Johann Karl³, Niklas Mattsson¹, Kaj Blennow², Udo Eichenlaub³; Oskar Hansson¹ ((1) Clinical Memory Research Unit, Lund University, Sweden; (2) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden (3) Roche Diagnostics GmbH, Penzberg, Germany)

OC33: Concordance of Florbetapir (18F) Pet And Elecsys® Β-Amyloid(1-42) Csf Immunoassay in the Cread (Bn29552) Study of Crenezumab In Prodromal-To-Mild Ad. Timo Grimmer¹, Christina Rabe², Mercidita Navarro², David Clayton², Ekaterina Manuilova³, Udo Eichenlaub³, Jillian Smith⁴, Susanne Ostrowitzki², Lee Honigberg², Tobias Bittner⁵ ((1) Department of Psychiatry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; (2) Genentech, Inc., South San Francisco, CA, USA; (3) Roche Diagnostics GmbH, Penzberg, Germany; (4) Roche Products Ltd., Welwyn Garden City, UK; (5) F. Hoffmann-La Roche Ltd., Basel, Switzerland)

OC34: Development of Aβ, Tau and Cognitive Changes During The Time Course of Sporadic Alzheimer'S Disease. Niklas Mattsson¹, Oskar Hansson¹, Michael W. Weiner², Philip S. Insel^1,2 ((1) Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden; (2) Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA)

OC35: U.S. Pointer: Study Design and Trial Kickoff. Laura Baker¹, Mark Espeland¹, Miia Kivipelto^2,3, Gustavo Jimenez-Maggiora⁴, Martha Clare Morris⁵, Rema Raman⁴, Scott Rushing¹, Heather M. Snyder⁶, Jeff Williamson¹, Rachel Whitmer⁷, Nancy Woolard¹, Maria C. Carrillo⁶ On Behalf of the U.S. POINTER Study Team ((1) Wake Forest School of Medicine, Winston-Salem, NC, USA; (2) Karolinska Institutet, Solna, Sweden; (3) National Institute for Health and Welfare, Helsinki, Finland; (4) Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles, CA, USA; (5) Rush University Medical Center, Chicago, IL, USA; (6) Alzheimer's Association, Chicago, IL, USA; (7) University of California -Davis, Davis, CA, USA)

OC36: Implications for Ad Clinical Trials and Opportunities to Leverage The First Alzheimer'S Association U.S. National Best Clinical Practice Guidelines for the Evaluation Of Cognitive Behavioral Syndromes, Alzheimer'S Disease And Related Dementias. Alireza Atri^1,2, Mary Norman³, David S. Knopman⁴, Jason Karlawish⁵, Mary Sano⁶, Carolyn Clevenger⁷, Chiadi U Onyike⁸, Susan Scanland⁹, Paige Lin¹⁰, James Hendrix¹¹, Maria C. Carrillo¹¹, Brad C. Dickerson¹² and Alzheimer's Association Best Clinical Practices Workgroup ((1) Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA; (2) Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; (3) Erickson Living, Dallas, TX, USA; (4) Mayo Clinic, Rochester, MN, USA; (5) University of Pennsylvania, Philadelphia, PA, USA; (6) James J. Peters VA Medical Center, New York, NY, USA; (7) Emory University, Atlanta, GA, USA; (8) Johns Hopkins University, Baltimore, MD, USA; (9) Dementia Connection, Clarks Summit, PA, USA; (10) Tufts Medical Center, Boston, MA, USA; (11) Alzheimer's Association, Chicago, IL, USA (12)Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA)

OC37: Pros and Cons of Ad Composite Endpoints Considering Recently Revised Regulatory Guidance and 2018 Nia-Aa Research Framework. Michael T. Ropacki¹, Suzanne Hendrix² ((1) Strategic Global Research & Development, Half Moon Bay, USA; (2) Pentara Corporation, Salt Lake City, USA)

OC38: The European Prevention of Alzheimer’S Dementia (Epad); Summary of First Formal Data Lock (Epad V500.0) and Predictors of Amyloid Status. Craig Ritchie¹, Graciela Muniz-Terrera¹, Serge Van der Geyten², Miia Kivipelto³, Alina Soloman³, Brian Tom⁴, Jose Luis Molinuevo⁵ ((1) Dementia Prevention Research Group, University of Edinburgh, UK; (2) Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; (3) Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet and Karolinska University Hospital, Sweden; (4) MRC Biostatistics Unit, University of Cambridge, UK; (5) Barcelona Beta Brain Research Centre, Spain)

LATE BREAKING NEWS

LB1: Results from the Phase 2 Navigate-Ad Clinical Trial Evaluating Ly3202626 Bace Inhibitor in Patients With Mild Alzheimer'S Disease Dementia. Albert C Lo¹, Cynthia Duggan Evans¹, Michele Mancini¹, Qun Lin, Hong Wang¹, Peng Liu¹, Sergey Shcherbinin¹, Ming Lu², Arnaud Charil¹, Brian A Willis¹, Michael Irizarry³ ((1) Eli Lilly and Company, Indianapolis, IN, USA; (2) Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, USA; (3) Eli Lilly and Company, Indianapolis IN, USA; now at Eisai Inc, Woodcliff Lake, NJ)

LB2: Tommorrow: A Trial to Delay The Onset of Mci Due to Ad and Qualify a Genetic Biomarker Algorithm: Topline Results. Robert Alexander1, Daniel K. Burns2, Kathleen A. Welsh-Bohmer3, Carl Chiang2, Meredith Culp4, Janet O'Neil4, Brenda L. Plassman3, Craig Metz2, Deborah Yarbrough4, Jingtao Wu1, Rebecca Evans1, Kumar Budur4, Stephen K. Brannan4, Ann M. Saunders2, Emiliangelo Ratti1 for the TOMMORROW Study Investigators ((1) Takeda Development Center Americas, Inc., Cambridge, MA, USA; (2) Zinfandel Pharmaceuticals, Inc., Durham, NC, USA; (3) Duke University Bryan ADRC, Durham, NC, USA; (4) Takeda Development Center Americas, Inc., Deerfield, IL, USA)

LB3: Lu Af20513, an Active Immunotherapy Against Amyloid Beta, in Development For Patients in Early Stages of Alzheimer'S Disease. Bjørn Sperling, Lars Østergaard Pedersen, Neli Boneva, Dorthe Daugaard, Yudong Zhao (H. Lundbeck A/S, Valby, Denmark)

LB4: Predictors Of [18F]Flortaucipir (Tau) Load in Alzheimer's Disease and Other Neurodegenerative Disorders. Oskar Hansson^1,2, Gil D. Rabinovici³, Chul H. Lyoo⁴, Rik Ossenkoppele^1,5 ((1) Lund University, Clinical Memory Research Unit, Lund, Sweden; (2) Memory Clinic, Skåne University Hospital, Malmö, Sweden; (3) Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center; (4) Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea; (5) VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands)

LB5: 18F-AV-1451-A16: A Clinico-Pathological Study of the Correspondence Between Flortaucipir Pet Imaging and Post-Mortem Assessment of Tau Pathology. Mark A. Mintun^1,2, Adam S. Fleisher², Michael D. Devous², Ming Lu², Anupa K. Arora², Thomas G. Beach³, Thomas J. Montine⁴, Michael J. Pontecorvo² ((1) Eli Lilly and Company, Indianapolis, IN, USA; (2) Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA; (3) Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA; (4) Department of Pathology, Stanford University, Stanford, CA, USA)

LB6: Age and Apoe Genotype-Specific Population Frequencies of Cerebral Β-Amyloidosis And Hippocampal Atrophy Among Cognitively Normal Individuals in Chariot-Pro. Hany Rofael¹, Gerald Novak¹, Luc Bracoud², Nandini Raghavan¹, Ziad Saad³, S Einstein¹, Robert Brashear¹, David Scott⁴, Joel Schaerer², Celeste de Jager⁵, Chi Udeh-Momoh⁵, the Alzheimer's Disease Neuroimaging Initiative (ADNI), Lefkos Middleton⁵ ((1) Janssen Research and Development, Titusville, NJ, USA; (2) Bioclinica, Lyon, France; (3) Janssen Research and Development, La Jolla, CA, USA; (4) Bioclinica, Newark, CA, USA; (5) Imperial College of London, London, UK)

LB7: Safety And Efficacy Results from the Phase 3, Multicenter, 18-Month Steadfast Trial of Azeliragon in Participants with Mild Alzheimer'S Disease. Marwan Sabbagh¹, Imogene Dunn², Ann Gooch², Tom Soeder³, Karl Kieburtz⁴, Carmen Valcarce², Larry D Altstiel², Aaron H Burstein² ((1) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; (2) vTv Therapeutics LLC, High Point, NC, USA; (3) Cato Research LTD, Durham, NC, USA; (4) Clintrex LLC, Longboat Key, FL, USA)

LB8: Aducanumab Titration Dosing Regimen: 36-Month Analyses From Prime, A Phase 1B Study In Patients With Early Alzheimer'S Disease. Samantha Budd Haeberlein¹, Carmen Castrillo-Viguera¹, Tianle Chen¹, John O'Gorman¹, Raj Rajagovindan¹, Dakshaben Patel², Philipp von Rosenstiel¹, Guanfang Wang³, Spyros Chalkias¹, LeAnne Skordos¹, Claudia Prada¹, Christoph Hock⁴, Roger M Nitsch⁴, Alfred Sandrock¹ ((1) Biogen, Cambridge, MA, USA; (2) Biogen, Maidenhead, UK; (3) Cytel, Cambridge, MA, USA; (4) Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland)

LB9: Longitudinal 148-Week Extension Study for Anavex®2-73 Phase 2A Alzheimer'S Disease Demonstrates Maintained Activities Of Daily Living Score (Adcs-Adl) and Reduced Cognitive Decline (Mmse) for Patient Cohort On Higher Drug Concentration and Confirms Role Of Patient Selection Biomarkers. Harald Hampel¹, Mohammad Afshar², Frédéric Parmentier², Coralie Williams², Adrien Etcheto², Federico Goodsaid³, Christopher U Missling⁴ ((1) Department of Neurology, Sorbonne University, Paris, France; (2) Ariana Pharma, Paris, France; (3) Regulatory Pathfinders LLC, San Francisco, CA; (4) Anavex Life Sciences Corp., New York, NY)

LB10: Predictive Performance of Csf And Imaging Ad Biomarkers in Adni1/Go/2 Mci Participants Using the Nia-Aa Research Framework. Leslie M Shaw¹, Michal Figurski¹, Susan Landau², William Jagust², Clifford R Jack³, Paul S Aisen⁴, Ronald C Petersen³, Michael W Weiner⁵, John Q Trojanowski¹ ((1) University of Pennsylvania, Philadelphia, USA; (2) University of California, Berkeley, Berkeley, USA; (3) Mayo Clinic, Rochester, USA; (4) University of Southern California, San Diego, USA; (5) University of California, San Francisco – San Francisco, USA)

Preliminary Analyses of Data from an Ongoing Trial of Atabecestat in Preclinical Alzheimer'S. Gary Romano¹, Nandini Raghavan¹, Yevgen Tymofyeyev¹, Reisa Sperling², Paul Aisen³, Rema Raman³, David Henley¹ ((1) Janssen Research and Development LLC, NJ, USA; (2) Brigham and Women's Hospital, Boston, MA, USA; (3) Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles, CA, USA)

Export

Vol 5 - N° S1

P. 1-45 - octobre 2018 Retour au numéro

Article précédent

Symposia

| Article suivant

Posters

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Symposia - 21/11/24

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL